Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamics and Efficacy of MK-7288 in Adults With Sleep Apnea (MK-7288-010)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Female participants are of non-child-bearing potential.~* Male participants who have female partner(s) of child-bearing potential must agree to use a medically acceptable method of contraception during the study.~* Participant has an International Classification of Sleep Disorders diagnosis of Obstructive Sleep Apnea/Hypopnea Syndrome.~* Participant has excessive daytime sleepiness.~* Participant has been using nCPAP treatment for at least 2 months.~* Participant reported total sleep time of \>6 hours on at least 4 out of 7 nights each week~* Participant is willing to stay at the sleep laboratory for 5 overnight stays.~* Participant is willing to limit caffeine and alcohol consumption during the study.~* Participant has a valid driver's license in the past 5 years and has had at least 1 year of driving experience within the past 3 years.~* Participant's regular bedtime is between 9:00 p.m. and 12:00 a.m.~Exclusion Criteria:~* Participant has a history of cancer.~* Participant has any history of a significant neurological disorder.~* Participant has moderate or severe persistent asthma.~* Participant has a history of any of the following sleep disorders: narcolepsy, primary insomnia, Circadian rhythm sleep disorder, shift work sleep disorder, parasomnia including nightmare disorder, sleep terror disorder, rapid eye movement (REM) behavioral disorder, and sleepwalking disorder, periodic limb movement disorder, or restless leg syndrome.~* Participant consumes more than 10 cigarettes a day or routinely smokes during the night.~* Participant, in the opinion of the investigator, has a history or current evidence of any condition, therapy, lab abnormality or circumstances that might confound the results of the study, or interfere with participation for the full duration of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- MK-7288 10mg/Pbo/MK-7288 20mg/Modafinil (Type: EXPERIMENTAL): Participants received single doses of study drug in the following order: MK-7288 10 mg in Treatment Period 1, Placebo (Pbo) in Treatment Period 2, MK-7288 20 mg in Treatment Period 3 and Modafinil 200 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
- MK-7288 20mg/MK-7288 10mg/Modafinil/Pbo (Type: EXPERIMENTAL): Participants received single doses of study drug in the following order: MK-7288 20 mg in Treatment Period 1, MK-7288 10 mg in Treatment Period 2, Modafinil 200 mg in Treatment Period 3 and Placebo in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
- Modafinil/MK-7288 20mg/Pbo/MK-7288 10mg (Type: EXPERIMENTAL): Participants received single doses of study drug in the following order: Modafinil 200 mg in Treatment Period 1, MK-7288 20 mg in Treatment Period 2, Placebo in Treatment Period 3 and MK-7288 10 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
- Pbo/Modafinil/MK-7288 10 mg/MK-7288 20mg (Type: EXPERIMENTAL): Participants received single doses of study drug in the following order: Placebo in Treatment Period 1, Modafinil 200 mg in Treatment Period 2, MK-7288 10 mg in Treatment Period 3 and MK-7288 20 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.

Based on this trial design, predict the completion outcome and termination type (if applicable).